Mildronate for Acute Ischemic Stroke
Mildronate for Acute Ischemic Stroke
Mildronate an inhibitor of carnitine-dependent metabolism, is considered an anti-ischemic
 drug. This study aims to evaluate the efficacy and safety of mildronate injection in treating
 acute ischemic stroke.
A randomized, double-blind, multi-center clinical study was made on mildronate injection for
 treating acute cerebral infarction. 113 cases in the experimental group were given with
 mildronate injection, while 114 cases in the active-control group were given with cinepazide
 maleate injection. In addition, both groups were given aspirin as basic treatments. Modified
 Rankin Scale (mRS) score at 2 weeks and 3 months, National Institutes of Health Stroke Scale
 (NIHSS) score and Barthel Index score at 2 weeks after treatment, vital signs and adverse
 events were evaluated.
Inclusion Criteria:

 -  (i) had a clinical diagnosis of acute ischaemic stroke ,on the first episode within
 the previous 7 days, and confirmed on CT or MRI brain imaging.(ii) were between 18 to
 80 years of age (patients >= 70 years were not combined with any other poor physical
 condition except ischaemic stroke )(iii)had a score of 5-22 on the National Institutes
 of Health Stroke Scale (NIHSS).(iv)had a report that liver and kedney function were
 less than 1.5 folds of normal value.

 Exclusion Criteria:

 -  (i) had other intracranial pathologies (e.g. cerebral hemorrhage, tumour, infection),
 (ii) were pregnant or nursing ;(iii) had a neurological or psychiatric disease ;(iv)
 had significant drug or alcohol misuse, (v)had been given thrombolytic therapy or
 medication forbidden by study protocol; (vi)participated in a clinical trial in the
 past 3 months.